Skip to main content
Premium Trial:

Request an Annual Quote

NextPharma to Manufacture Epigenomics' Colon Cancer Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – NextPharma will manufacture Epigenomics' colon cancer test for certain markets worldwide, the firms announced today.

Under terms of the deal, NextPharma will manufacture Epigenomics' Epi proColon test kit in Europe and other markets and will manufacture a cGMP-compliant version of the test, which is currently under development, for the US market.

The test, which identifies the presence of methylated DNA of the Septin9 gene, is CE-marked in Europe. Berlin, Germany-based Epigenomics plans to file for US marketing clearance of the test next year.

Surrey, UK-based NextPharma will manufacture the Epi proColon test at its facilities in San Diego, which are ISO 13485 certified for manufacturing medical devices.

"In NextPharma we have found the ideal contract manufacturing partner to satisfy the increasing demand for our Epi proColon test kit in Europe," Uwe Staub, SVP of product development for Epigenomics, said in a statement.

Financial and other terms of the agreement were not disclosed.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.